Clinical Trials Directory

Trials / Not Yet Recruiting

Not Yet RecruitingNCT06943664

Photoimmunotherapy With ASP-1929 and Cemiplimab for the Treatment of Refractory, Inoperable, and Metastatic Stage IIIB-IV Non-small Cell Lung Cancer

Phase II Trial: Photoimmunotherapy and Anti-PD1 in Patients With Refractory Inoperable and Metastatic Non-Small Cell Lung Cancer

Status
Not Yet Recruiting
Phase
Phase 2
Study type
Interventional
Enrollment
27 (estimated)
Sponsor
Roswell Park Cancer Institute · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This phase II trial tests how well photoimmunotherapy (PIT) with ASP-1929 in combination with cemiplimab works in treating patients with stage IIIB-IV non-small cell lung cancer (NSCLC) that has not responded to previous treatment (refractory), that is not suitable for surgery (inoperable), or that has spread from where it first started to other places in the body (metastatic). PIT is a treatment that combines drugs that become active when exposed to light, such as ASP-1929, with immunotherapy to target and kill tumor cells. ASP-1929 combines cetuximab with a light-sensitive component, sarotalocan. Cetuximab is in a class of medications called monoclonal antibodies. It binds to a protein called epidermal growth factor receptor (EGFR), which is found on some types of tumor cells. This may help keep tumor cells from growing. Sarotalocan is a fluorescent dye, infrared-activated fluorescent dye 700, that is light sensitive, and when activated by a special type of laser light, helps destroy or change tumor cells. Immunotherapy with monoclonal antibodies, such as cemiplimab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Giving PIT with ASP-1929 in combination with cemiplimab may kill more tumor cells in patients with refractory, inoperable, or metastatic stage IIIB-IV NSCLC.

Detailed description

PRIMARY OBJECTIVE: I. To assess objective response rate of tumors and lymph nodes following photoimmunotherapy and anti-PD1. SECONDARY OBJECTIVES: I. Overall survival following photoimmunotherapy and anti-PD1. II. To assess median progression free survival following photoimmunotherapy and anti-PD1. III. To assess the relationship between light irradiance and fluence dose volume histograms and objective tumors response following photoimmunotherapy and anti-PD1. IV. To evaluate the safety of cetuximab sarotalocan sodium (ASP-1929) photoimmunotherapy in combination with immune checkpoint inhibitors in patients with refractory inoperable and metastatic non-small cell lung cancer. EXPLORATORY OBJECTIVES: I. To assess the relationship between changes of circulating tumor deoxyribonucleic acid (DNA) (ctDNA) levels and objective response of tumors. II. To assess the relationship between levels of EGFR expression and the objective response of tumors. OUTLINE: Patients receive cemiplimab intravenously (IV) over 30 minutes on days 1, 22, and 43 of each cycle and ASP-1929 IV over 2 hours on day 8 of each cycle. Patients undergo external beam (EB)-PIT via standard of care video-assisted thoracic surgery (VATS) once on day 9 of cycle 1 or interstitial (I)-PIT via endobronchial ultrasound (EBUS) or robotic bronchoscopy up to 3 times on day 9 of cycles 1, 2, and/or 3. Cycles repeat every 9 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo blood sample collection, computed tomography (CT) and/or positron emission tomography (PET)/CT or magnetic resonance imaging (MRI) throughout the study. After completion of study treatment, patients are followed up every 3 months for up to 2 years.

Conditions

Interventions

TypeNameDescription
PROCEDUREBiospecimen CollectionUndergo blood sample collection
BIOLOGICALCemiplimabGiven IV
BIOLOGICALCetuximab Sarotalocan SodiumGiven IV
PROCEDUREComputed TomographyUndergo CT or PET/CT
OTHERElectronic Health Record ReviewAncillary studies
PROCEDUREEndobronchial Ultrasound BronchoscopyUndergo EBUS
PROCEDUREMagnetic Resonance ImagingUndergo MRI
PROCEDUREPhotoimmunotherapyUndergo EB-PIT
PROCEDUREPhotoimmunotherapyUndergo I-PIT
PROCEDUREPositron Emission TomographyUndergo PET/CT
PROCEDURERobotic BronchoscopyUndergo robotic bronchoscopy
PROCEDUREVideo-Assisted Thoracic SurgeryUndergo VATS

Timeline

Start date
2026-05-15
Primary completion
2027-05-01
Completion
2028-05-01
First posted
2025-04-24
Last updated
2026-03-24

Locations

1 site across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT06943664. Inclusion in this directory is not an endorsement.